실적분석 2026년 8월 3일

GeneDx Holdings ($WGS) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat, Full-Year Guidance Maintained

Earnings Scorecard

Revenue: $114.4 million (up 11% year over year, estimate $111 million) ✅ Beat

EPS: $0.01 on an adjusted basis (estimate $(0.19)) ✅ Beat

Guidance: Maintained — full-year 2026 revenue of $475–$490 million reconfirmed; new Q3 revenue outlook of $122–$124 million and approximately $2 million in adjusted net income introduced

Stock reaction: +11.92% after-hours ($75.95) — as of 08-04 06:12 Korea time

The Positives

Revenue beat: Q2 revenue of $114.4 million exceeded the $111 million estimate and rose 11% from a year earlier

Return to adjusted profit: Adjusted net income of $0.4 million and adjusted EPS of $0.01 marked a sharp improvement from Q1

Surge in core test volume: Exome and genome result volume of 30,785 cases, up 32% year over year

GeneDx Holdings ($WGS), whose core business is rare-disease genomic diagnostics, posted total revenue of $114.4 million in Q2 2026 (April–June). The figure topped the $111 million the market was looking for and was up 11% from approximately $102.7 million a year earlier. Within that, exome and genome testing revenue reached $100.3 million, climbing 17% year over year and serving as the central engine of overall growth.

Adjusted gross margin was 70%, slightly above Q1's 69%, while adjusted net income of $0.4 million improved by $8.6 million versus Q1 to swing back into the black. Adjusted EPS of $0.01 represents a sizable beat relative to the consensus $(0.19). Broader access from expanded coverage across Texas and California Medicaid as well as Carelon and other payers is also being read as a longer-term volume-growth narrative.

The Negatives

GAAP remains in the red: GAAP net loss of $17.7 million, or a $(0.60) loss per share

Sharp year-over-year decline in adjusted earnings: Adjusted net income of $0.4 million is a steep drop from $16.4 million in the prior-year period

Revenue growth lags volume: Exome and genome volume rose 32%, but the corresponding revenue grew only 17%, signaling pricing pressure

Even as the company returned to adjusted profitability, on a GAAP basis it still recorded a Q2 net loss of $17.7 million (a $(0.60) loss per common share). Because non-cash and one-time items such as stock-based compensation, depreciation, and restructuring charges are excluded from the adjusted figures, novice investors should be careful not to treat "adjusted profit" and "book loss" as the same thing.

Set against adjusted net income of $16.4 million in the prior-year quarter, this year's Q2 adjusted earnings shrank sharply. A meaningful increase in operating expenses, including SG&A, was a major driver. In addition, exome and genome volume grew 32%, while the associated revenue rose only 17%, leaving open the possibility that per-unit pricing or mix during the transition toward genomic testing failed to keep pace with revenue growth. As of the end of June, cash and marketable securities stood at $133.5 million, supplemented by an estimated $188 million in proceeds tied to a Blackstone-related transaction, but operating cash outflows in the first half mean cost discipline and pricing recovery will be key.

What Management Said

Management characterized the quarter as one of "profitability recovery," emphasizing that revenue, volume, and gross margin all moved in the right direction together. The framing is that the company is managing the transition toward genomic testing while simultaneously advancing its three core priorities: improving unit economics, expanding utilization, and scaling product supply. The full-year revenue guidance was reaffirmed within the existing range, and for Q3 the company put forward specific revenue and adjusted net income targets to sharpen near-term visibility.

The market appears to have taken the revenue and adjusted earnings beats, the reiteration of full-year guidance, and the expanded payer coverage news as a continuation of the growth-and-profitability story. That said, the GAAP loss and the thinner year-over-year adjusted earnings leave a reminder that the "return to profitability" narrative will need to be validated again next quarter.

Market Reaction and What to Watch Next

The market appears to have taken a positive view on revenue and adjusted earnings coming in above expectations, full-year guidance being held, and the additional visibility provided by the Q3 adjusted net income target. The swing back to adjusted profitability from Q1, combined with news of expanded payer coverage, also helped reinforce confidence that "growth is flowing through to the numbers." The after-hours move in the scorecard reflects those expectations being priced in at once, and whether the next regular trading session's volume confirms follow-through will determine whether the move has staying power.

Whether the company delivers on its Q3 targets of $122–$124 million in revenue and roughly $2 million in adjusted net income.

Whether the growth in exome and genome volume translates more evenly into revenue and gross margin, and whether per-unit pricing pressure eases.

Whether the GAAP loss narrows and operating cash flow improves, along with the pace of cost deployment following the funding event.